Abstract
Parkinson’s Disease (PD) is the most prevalent neurodegenerative disorder after Alzheimer’s, yet its diagnosis largely relies on subjective clinical assessments. Thus, this study proposes a systematic, data-driven approach to accurately classify PD patients using heterogeneous risk factors along with efficient machine learning. Six machine learning algorithms, Support Vector Machine(SVM), Random Forest(RF), Extreme Gradient Boosting(XGBoost), Logistic Regression(LR), K-Nearest Neighbour (KNN), and Decision Tree(DT) were utilized and evaluated their performances to identify the most robust and efficient model with high discrimination power. SVM model outper-formed all other machine learning models, and it has been identified as the highest-quality model to classify PD patients from others with at least 96% accuracy. Further-more, Feature importance was analyzed using SHAP to enhance the interpretability of the proposed model. This study contributes to the integration of artificial intelligence in the healthcare domain, emphasizing the value of data-driven classification modeling techniques in supporting healthcare professionals with accurate, personalized, and actionable insights for high-risk patients. Together, these approaches enhance the precision of early detection of PD, paving the way for more informed clinical decision-making and improved patient care.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
N/A
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data used in the preparation of this article was obtained on [2021-10-18] from the Parkinson's Progression Markers Initiative (PPMI) database (www.ppmi-info.org/accessdataspecimens/download-data), RRID: SCR˙006431. For up-to-date information on the study, visit www.ppmi-info.org.
